Insiders who bought this year lost US$50k as Harpoon Therapeutics, Inc. (NASDAQ:HARP) sheds US$30m in value
The recent price decline of 22% in Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) stock may have disappointed insiders who bought US$83k worth of shares at an average price of US$8.10 in the past 12 months. Insiders invest with the hopes of seeing their money grow in value over time. However, as a result of recent losses, their initial investment is now only worth US$33k, which is not what they expected.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Check out our latest analysis for Harpoon Therapeutics
The Last 12 Months Of Insider Transactions At Harpoon Therapeutics
In the last twelve months, the biggest single purchase by an insider was when Chief Financial Officer Georgia Erbez bought US$83k worth of shares at a price of US$8.10 per share. That means that an insider was happy to buy shares at above the current price of US$3.25. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. The only individual insider to buy over the last year was Georgia Erbez.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Harpoon Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Does Harpoon Therapeutics Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$1.3m worth of Harpoon Therapeutics stock, about 1.2% of the company. I generally like to see higher levels of ownership.
So What Does This Data Suggest About Harpoon Therapeutics Insiders?
The fact that there have been no Harpoon Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think Harpoon Therapeutics insiders are doubting the company. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example - Harpoon Therapeutics has 2 warning signs we think you should be aware of.
But note: Harpoon Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
